NASDAQ: SNPXSynaptogenix Inc Stock
$3.45-0.11 (-3.09%)
Updated Sep 6, 2024
SNPX Price
$3.45
Fair Value Price
N/A
Market Cap
$4.53M
52 Week Low
$3.27
52 Week High
$11.48
P/E
0.67x
P/B
0.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.51
Operating Cash Flow
-$5M
Beta
1.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SNPX Overview
Synaptogenix Incorporated is a biopharmaceutical company developing a product platform for the treatment of Alzheimer's based upon a drug candidate called Bryostatin-1. It is also assessing therapeutic applications of Bryostatin-1 for other neurodegenerative and cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-Pick Type C disease. Synaptogenix was incorporated in 2012 and is headquartered in New York, NY.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SNPX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNPX is good value based on its earnings relative to its share price (0.67x), compared to the US market average (24.57x)
P/E vs Market Valuation
SNPX is good value based on its earnings relative to its share price (0.67x), compared to the US Biotechnology industry average (-46.85x)
P/E vs Industry Valuation
SNPX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more SNPX due diligence checks available for Premium users.
Be the first to know about important SNPX news, forecast changes, insider trades & much more!
SNPX News
Valuation
SNPX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.67x
Industry
-46.85x
Market
24.57x
SNPX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SNPX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SNPX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.24x
Industry
6.22x
SNPX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNPX's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.3M
Profit Margin
0%
SNPX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$28.4M
Liabilities
$9.6M
Debt to equity
0.51
SNPX's short-term assets ($27.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNPX's short-term assets ($27.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNPX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$853.5k
Investing
-$500.0k
Financing
$0.0
SNPX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SNPX vs Biotech Stocks
Synaptogenix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.